Savara Molgramostim FDA Decision Delayed: No New Date for First aPAP Drug
The FDA will miss the 22 November goal date for Savara’s inhaled molgramostim in autoimmune PAP and has set no new date. What happened, the regulatory history and what analysts expect.
